Comment on: “role of sonazoid-based contrast-enhanced ultrasonography in the microwave ablation of primary hyperparathyroidism” by Zu-Bang Zhou et al. on Int. J. of Hyperthermia. 2022;39(1):155–161

The authors seem to confuse Sonovue with Sonazoid. The manuscript is entitled ‘Role of Sonazoid-based contrast-enhanced ultrasonography in the microwave ablation of primary hyperparathyroidism’. But there are several references to Sonovue in the text, as follow:

1. ‘Introduction’ Part

‘To our knowledge, no study has reported on the application of the contrast agent Sonazoid in evaluating the therapeutic effect of MWA for pHPT. Therefore, we aimed to determine the performance of Sonazoid-based CEUS and assess if it results in complete ablation in patients with pHPT, thereby increasing the cure rate’.

2. ‘Methods-CEUS examination’ Part

‘the US contrast agent was Sonovue (Bracco, Milan, Italy)’

3. ‘Discussion’ Part

‘The contrast agent Sonazoid consists of several biocompatible materials containing low solution and infusibility gases, such as sulfur hexafluoride’.

Sonovue is made of sulfur hexafluoride, while Sonazoid is perfluorobutane. To the best of my knowledge, in China, the indication for Sonazoid is limited to focal liver lesions.

Disclosure statement

No potential conflict of interest was reported by the author.